[Rifaximin improves clinical symptoms and short-term survival in cirrhotic patients with refractory type ascites].

Wang, Z; Hou, W; Zhang, W; Wu, H X; Zheng, S J; Hu, Z J

Wang, Z; Hou, W; Zhang, W; Wu, H X; Zheng, S J; Hu, Z J.

Afiliação

Wang Z; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Hou W; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhang W; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Wu HX; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zheng SJ; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Hu ZJ; First Department of the Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Zhonghua Gan Zang Bing Za Zhi ; 30(11): 1170-1174, 2022 Nov 20.

Article em Zh | MEDLINE | ID: mdl-36891693

Assuntos

Encefalopatia Hepática; Rifamicinas; Humanos; Rifaximina/uso terapêutico; Rifamicinas/uso terapêutico; Ascite/etiologia; Estudos Retrospectivos; Cirrose Hepática/tratamento farmacológico; Encefalopatia Hepática/complicações; Resultado do Tratamento; Peso Corporal

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifamicinas / Encefalopatia Hepática Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: Zh Revista: Zhonghua Gan Zang Bing Za Zhi Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google